OR WAIT 15 SECS
© 2021 MJH Life Sciences and Dermatology Times and Multimedia Medical, LLC. All rights reserved.
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
February 10, 2020
It’s known that combination therapies can be used to create ideal treatment outcomes, but according to Dr. Suneel Chilukuri, results may also last longer than originally thought.
February 03, 2020
Millennials think of aesthetic treatments no differently than other beauty appointments, according to Dr. Ava Shamban. These are their top facial concerns.
January 29, 2020
In a skit depicting Carnac the Magnificent, Drs. Rosen and Bhatia presented on 2020's new drugs and technologies at the current Maui Derm for Dermatologists, all with a magical twist.
January 28, 2020
In his presentation at the current Maui Derm 2020, Dr. Curtis Cole tackled the controversy of how SPF labeling can differ significantly from the actual protection.
January 22, 2020
An analysis by Vanguard Communications suggests more weight is attached to physician patient reviews compared to those of hotels and restaurants.
January 21, 2020
A recent study reports findings that support dupilumab as a safe, long-term treatment in patients with moderate-to-severe atopic dermatitis.
With advancements in deep next-generation sequencing (NGS) and bioinformatics analysis, the authors of a recent study suggest the skin microbiome may hold promise as a clinical biomarker in atopic dermatitis (AD) management.
January 16, 2020
Off-label product use is fairly common in aesthetics and plays a key role in advancing treatment practices in the specialty. Dr. Amy Foreman Taub explains the four she uses on a regular basis.
Recent phase 3 clinical trials reveal positive results for tazarotene lotion 0.045% in patients with moderate-to-severe acne.
January 13, 2020
The distribution agreement between Revance and Swiss HA-based dermal filler and cosmeceutical manufacturing company, TEOXANE SA, may position Revance as a leader in the U.S. facial injectable market.